Clinical Trust
The scientific community trusts Freelite assays
Freelite tests have been the assay of choice for clinicians and laboratories worldwide for over 20 years. With a significant presence in over 3800 scientific papers, Freelite assays have solidified their reputation for performance and accuracy. Beyond the numbers and scientific accolades, there is a human aspect to diagnostics. Every test result represents a patient with their story and hopes for a healthier future, and Freelite assays can have a profound impact on these patient journeys.
Our commitment to improving patient outcomes is showcased through a series of clinical impact case studies. These stories highlight the reasons why the medical community places their trust in Freelite assays. Each case study demonstrates the pivotal role that Freelite assays played in accurate diagnosis, treatment monitoring, and disease management. From early detection of disease to guidance of treatment decisions, Freelite assays empower healthcare professionals to make the better-informed choices for their patients.
Discover the full stories
Learn more about the impacts of Freelite assays on patient journeys and discover the stories that reinforce why they are trusted by the medical community worldwide:
Impact on kidney function
Hastily admitted to hospital with acute deterioration of the kidney function, a 68-year-old Multiple Myeloma patient was in VGPR since 2015. The N Latex Free Light Chain (FLC) assay from Siemens failed to signal relapse; and the patient’s journey led to permanent hemodialysis. Only when the patient was retested with Freelite assays, which yielded significantly higher FLC levels, was the disease progression signalled.
Discover the full story of this patient:
Signal disease progression
A change in the FLC testing had a drastic impact for an IgA λ Multiple Myeloma patient diagnosed in 2016 using Freelite assays. Monthly monitoring with the N Latex FLC assay failed to signal disease progression. The patient suffered kidney failure, which led to a general deterioration of health and ultimately death.
Discover the full story of this patient:
Guiding treatment decision
An 83-year-old patient was diagnosed with Multiple Myeloma in 2022. For both diagnosis and monitoring, the N Latex FLC assay failed to signal increasing λ FLC levels. When Freelite assays were used, it revealed the failure of the treatment, which led to the adjustment of therapy.
Download the full story of this patient:
Delayed diagnosis
This MM patient suffered multiple fractures, due to a delayed detection of the disease progression. The N Latex FLC assay had failed to signal the relapse. Re-evaluation using Freelite assays indicated disease relapse and the initiation of new lines of therapy.
Download the full story of this patient:
Misclassified as Smoldering Multiple Myeloma
Misclassified as Smoldering Multiple Myeloma (SMM) using N Latex FLC assay, this patient’s multiple myeloma was only revealed, two years later, during a clinical trial. New results based on Freelite assays led to the re-evaluation of the diagnosis, potentially preventing additional consequences of delayed diagnosis.
Download the full story of this patient:
Misclassified as Monoclonal Gammopathy of Undetermined Significance
This patient was misclassified as MGUS, where N-Latex FLC results were used. Retrospective testing using Freelite® assays correctly supported the diagnosis of plasma cell leukemia, a much rarer and aggressive form of MM.
Download the full story of this patient:
Veskovski et al. 2024
An independent peer-reviewed publication focused on a comparative study between Freelite® assays and N Latex FLC assays, revealing that 7 myeloma patients had been misclassified by N Latex FLC assay and were at risk of suffering significant and incapacitating clinical consequences, including renal failure, fractures, and even patient’s death.
Behind every assay result is a life waiting to be transformed. Our dedication to advancing diagnostics is driven by the desire to improve patient care and outcomes. By choosing Freelite assays, laboratories and healthcare professionals join a global community that prioritizes both scientific excellence and the human aspect of medicine.
Complete this form and we will get back to you
Freelite is a registered trademark of The Binding Site Group Ltd (Birmingham, UK) in certain countries. Other brand or product names may be trademarks of their respective holders.